Welcome to our dedicated page for Novo-Nordisk A/S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novo Nordisk A/S filings document the Danish healthcare company's financial reporting, product portfolio, pipeline progress and capital structure as a foreign private issuer. Form 6-K reports include operating and financial results, commercial updates for diabetes and obesity medicines, regulatory and clinical disclosures for products such as Wegovy, and development updates in areas including sickle cell disease.
The filing record also covers B-share repurchase programs, treasury-share ownership, share-capital information, governance matters and risk-related disclosures. These reports connect Novo Nordisk's chronic-disease business, GLP-1 franchise, biopharmaceutical research and shareholder-capital actions to formal regulatory disclosure.
Novo Nordisk (NVO) files a Form 6-K announcing a leadership overhaul effective 7 Aug 2025. Executive vice president for International Operations Maziar “Mike” Doustdar is promoted to president & CEO, succeeding long-time leader Lars Fruergaard Jørgensen. Doustdar has overseen International Operations sales growth to about DKK 112 bn in 2024 and manages nearly 20,000 employees across 80 affiliates.
The Board also merges the Research & Early Development and Development divisions into one R&D unit. Martin Holst Lange, currently EVP Development, becomes chief scientific officer, while incumbent CSO Marcus Schindler will retire after a transition period. Emil Kongshøj Larsen moves into Executive Management as EVP International Operations, succeeding Doustdar.
The revised Executive Management team will comprise nine members, including CFO Karsten Munk Knudsen and US EVP David Moore. Investor and media conference calls are scheduled for 29 July 2025 at 14:30 CEST and 16:00 CEST, respectively.